The Grass Pollen Allergy drugs in development market research report provides comprehensive information on the therapeutics under development for Grass Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Grass Pollen Allergy. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued products.

GlobalData tracks 11 drugs in development for Grass Pollen Allergy by ten companies/universities/institutes. The top development phase for Grass Pollen Allergy is phase ii with six drugs in that stage. The Grass Pollen Allergy pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Grass Pollen Allergy pipeline products market are: Allergy Therapeutics, DC4U and HAL Allergy.

The key targets in the Grass Pollen Allergy pipeline products market include Pituitary Adenylate Cyclase Activating Polypeptide (ADCYAP1), and Interleukin 4 Receptor Subunit Alpha (CD124 or IL4R).

The key mechanisms of action in the Grass Pollen Allergy pipeline product include Interleukin 4 Receptor Subunit Alpha (CD124 or IL4R) Antagonist with one drug in Phase II. The Grass Pollen Allergy pipeline products include three routes of administration with the top ROA being Subcutaneous and five key molecule types in the Grass Pollen Allergy pipeline products market including Allergenics (Allergen), and Monoclonal Antibody.

Grass Pollen Allergy overview

Grass pollen allergy is a reaction which occurs soon after exposure to pollen from grasses. Signs and symptoms include skin reactions such as hives, redness, or swelling; itching or tingling in or around the mouth and throat; tightening of the throat; shortness of breath or wheezing; and runny nose. Predisposing factors include age, family history, and other allergies.

For a complete picture of Grass Pollen Allergy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.